Published in Ann Neurol on August 22, 2012
Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice. Brain (2016) 1.41
Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models. J Clin Invest (2014) 1.15
Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia. J Neurosci (2013) 1.14
Cyclooxygenase-1-dependent prostaglandins mediate susceptibility to systemic inflammation-induced acute cognitive dysfunction. J Neurosci (2013) 1.13
Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling. J Neurosci (2014) 0.90
Inhibition of prostaglandin E2 receptor EP3 mitigates thrombin-induced brain injury. J Cereb Blood Flow Metab (2015) 0.88
Targeting innate immunity for neurodegenerative disorders of the central nervous system. J Neurochem (2016) 0.85
Therapeutic implications of the prostaglandin pathway in Alzheimer's disease. Biochem Pharmacol (2014) 0.85
Frataxin deficiency increases cyclooxygenase 2 and prostaglandins in cell and animal models of Friedreich's ataxia. Hum Mol Genet (2014) 0.84
The Role of Inflammatory Mediators in the Pathogenesis of Alzheimer's Disease. Sultan Qaboos Univ Med J (2015) 0.84
Anti-Inflammatory Small Molecules To Treat Seizures and Epilepsy: From Bench to Bedside. Trends Pharmacol Sci (2016) 0.83
Prostaglandin E2 receptor subtype 2 regulation of scavenger receptor CD36 modulates microglial Aβ42 phagocytosis. Am J Pathol (2014) 0.82
The effects of tamoxifen on learning, memory and brain tissues oxidative damage in ovariectomized and naïve female rats. Adv Biomed Res (2014) 0.79
The effects of tamoxifen on spatial and nonspatial learning and memory impairments induced by scopolamine and the brain tissues oxidative damage in ovariectomized rats. Adv Biomed Res (2015) 0.79
The Role of Dopamine and Its Dysfunction as a Consequence of Oxidative Stress. Oxid Med Cell Longev (2015) 0.78
Genetic deletion of the prostaglandin E2 E prostanoid receptor subtype 3 improves anatomical and functional outcomes after intracerebral hemorrhage. Eur J Neurosci (2015) 0.78
Inflammatory Cyclooxygenase Activity and PGE2 Signaling in Models of Alzheimer's Disease. Curr Immunol Rev (2015) 0.78
Inflammatory Eicosanoids Increase Amyloid Precursor Protein Expression via Activation of Multiple Neuronal Receptors. Sci Rep (2015) 0.77
Dual effects of noradrenaline on astroglial production of chemokines and pro-inflammatory mediators. J Neuroinflammation (2013) 0.77
Curcumin Ameliorates the Reduction Effect of PGE2 on Fibrillar β-Amyloid Peptide (1-42)-Induced Microglial Phagocytosis through the Inhibition of EP2-PKA Signaling in N9 Microglial Cells. PLoS One (2016) 0.76
Alzheimer disease: Prostaglandin E(2) signalling is implicated in inflammation early in the Alzheimer disease course. Nat Rev Neurol (2012) 0.75
EP3, Prostaglandin E2 Receptor Subtype 3, Associated with Neuronal Apoptosis Following Intracerebral Hemorrhage. Cell Mol Neurobiol (2015) 0.75
Clinical and Preclinical Cognitive Function Improvement after Oral Treatment of a Botanical Composition Composed of Extracts from Scutellaria baicalensis and Acacia catechu. Behav Neurol (2016) 0.75
Untangling the Web: Toxic and Protective Effects of Neuroinflammation and PGE2 Signaling in Alzheimer's Disease. ACS Chem Neurosci (2016) 0.75
Multi-targeted Imidazoles: Potential Therapeutic Leads for Alzheimer's and Other Neurodegenerative Diseases. J Med Chem (2017) 0.75
Microarray analysis of the in vivo response of microglia to Aβ peptides in mice with conditional deletion of the prostaglandin EP2 receptor. Genom Data (2015) 0.75
Fibrosis of the Choroid Plexus Filtration Membrane. J Neuropathol Exp Neurol (2016) 0.75
PGE2-EP3 signaling exacerbates intracerebral hemorrhage outcomes in 24-mo-old mice. Am J Physiol Heart Circ Physiol (2016) 0.75
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med (2001) 7.85
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature (2001) 7.35
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA (2003) 6.34
Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng (2001) 4.64
Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol (2002) 4.42
Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology (1996) 4.42
Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol (2001) 4.40
Risk of Alzheimer's disease and duration of NSAID use. Neurology (1997) 4.06
Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med (2003) 3.78
A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology (2005) 3.78
Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem (1997) 3.55
Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol (2002) 3.30
Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature (1998) 2.88
COX-2-derived prostacyclin confers atheroprotection on female mice. Science (2004) 2.87
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol (2008) 2.86
Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology (2004) 2.63
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology (2007) 2.54
Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J (2001) 2.52
Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis (2005) 2.22
Protective effects of NSAIDs on the development of Alzheimer disease. Neurology (2008) 2.21
Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology (1999) 2.16
Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol Biochem (2007) 2.12
EP3 prostaglandin receptors in the median preoptic nucleus are critical for fever responses. Nat Neurosci (2007) 2.05
Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci (2005) 1.89
Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement (2011) 1.87
Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis (2002) 1.85
COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol (2007) 1.77
Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat (2009) 1.69
Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol Aging (2007) 1.62
Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J Neurochem (2002) 1.44
The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol (2008) 1.38
Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity. Am J Pathol (2005) 1.38
Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein. J Neuroinflammation (2007) 1.30
The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol (2010) 1.26
GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS One (2008) 1.26
Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J Neurochem (2007) 1.23
Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neurosci Lett (2008) 1.19
Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. Int J Geriatr Psychiatry (2011) 1.16
Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience (2006) 1.15
Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2005) 1.15
Small molecule, non-peptide p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment. PLoS One (2008) 1.12
The increased activity of BACE1 correlates with oxidative stress in Alzheimer's disease. Neurobiol Aging (2007) 1.09
Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow. Am J Pathol (2010) 1.09
Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement Geriatr Cogn Disord (2006) 1.07
Signaling via the prostaglandin E₂ receptor EP4 exerts neuronal and vascular protection in a mouse model of cerebral ischemia. J Clin Invest (2011) 1.06
Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology. Int J Dev Neurosci (2004) 0.99
Involvement of phosphoinositide 3-kinase gamma in the neuro-inflammatory response and cognitive impairments induced by beta-amyloid 1-40 peptide in mice. Brain Behav Immun (2009) 0.95
Anti-amnesic effect of ESP-102 on Aβ(1-42)-induced memory impairment in mice. Pharmacol Biochem Behav (2010) 0.85
Regulation of calcium channels and exocytosis in mouse adrenal chromaffin cells by prostaglandin EP3 receptors. Mol Pharmacol (2011) 0.80
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Glucose levels and risk of dementia. N Engl J Med (2013) 4.95
Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol (2011) 4.76
Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol (2007) 4.47
Ballistic carbon nanotube field-effect transistors. Nature (2003) 4.35
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther (2004) 3.40
Fluorescence visualization of newly synthesized proteins in mammalian cells. Angew Chem Int Ed Engl (2006) 2.96
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol (2010) 2.91
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Severe fever with thrombocytopenia syndrome virus, Shandong Province, China. Emerg Infect Dis (2012) 2.77
Polarization-controlled tunable directional coupling of surface plasmon polaritons. Science (2013) 2.73
Improvement of Fat Graft Survival with Autologous Bone Marrow Aspirate and Bone Marrow Concentrate: A One-Step Method. Plast Reconstr Surg (2016) 2.59
A fluorogenic 1,3-dipolar cycloaddition reaction of 3-azidocoumarins and acetylenes. Org Lett (2004) 2.57
Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation (2006) 2.50
Cilium-generated signaling and cilia-related disorders. Lab Invest (2005) 2.42
Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci (2004) 2.40
Reversal of paralysis and reduced inflammation from peripheral administration of β-amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis. Sci Transl Med (2012) 2.38
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann Neurol (2003) 2.22
GFOLD: a generalized fold change for ranking differentially expressed genes from RNA-seq data. Bioinformatics (2012) 2.21
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology (2012) 2.19
The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol (2010) 2.19
High-kappa dielectrics for advanced carbon-nanotube transistors and logic gates. Nat Mater (2002) 2.18
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Modeling elastic properties in finite-element analysis: how much precision is needed to produce an accurate model? Anat Rec A Discov Mol Cell Evol Biol (2005) 2.01
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Differential stem- and progenitor-cell trafficking by prostaglandin E2. Nature (2013) 1.99
An investigation of the mechanisms of electronic sensing of protein adsorption on carbon nanotube devices. J Am Chem Soc (2004) 1.98
Effect of oral ALA supplementation on oxidative stress and insulin sensitivity among overweight/obese adults: a double-blinded, randomized, controlled, cross-over intervention trial. Int J Cardiol (2012) 1.98
OPTICAL COHERENCE TOMOGRAPHIC ANGIOGRAPHY IN CENTRAL SEROUS CHORIORETINOPATHY. Retina (2016) 1.93
Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell (2007) 1.90
Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res (2010) 1.89
Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci (2005) 1.89
Activation of RalA is required for insulin-stimulated Glut4 trafficking to the plasma membrane via the exocyst and the motor protein Myo1c. Dev Cell (2007) 1.88
Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement (2011) 1.87
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Electron transport in very clean, as-grown suspended carbon nanotubes. Nat Mater (2005) 1.86
Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest (2002) 1.86
Faster plasma vitamin E disappearance in smokers is normalized by vitamin C supplementation. Free Radic Biol Med (2005) 1.85
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol (2012) 1.84
Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis (2006) 1.82
Ecology of the aging human brain. Arch Neurol (2011) 1.78
Selective dye-labeling of newly synthesized proteins in bacterial cells. J Am Chem Soc (2005) 1.77
Selective vulnerability of preterm white matter to oxidative damage defined by F2-isoprostanes. Ann Neurol (2005) 1.77
Cilia and flagella revealed: from flagellar assembly in Chlamydomonas to human obesity disorders. Cell (2004) 1.76
Blood pressure and brain injury in older adults: findings from a community-based autopsy study. J Am Geriatr Soc (2009) 1.76
Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol (2009) 1.76
ABSORB: Atlas Building by Self-organized Registration and Bundling. Neuroimage (2010) 1.75
An aurora kinase is essential for flagellar disassembly in Chlamydomonas. Dev Cell (2004) 1.75
Thermal conductance of an individual single-wall carbon nanotube above room temperature. Nano Lett (2006) 1.73
LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol (2006) 1.72
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood (2010) 1.72
Free radical damage to cerebral cortex in Alzheimer's disease, microvascular brain injury, and smoking. Ann Neurol (2009) 1.71
Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res (2009) 1.70
High-field quasiballistic transport in short carbon nanotubes. Phys Rev Lett (2004) 1.68
The feeding biomechanics and dietary ecology of Australopithecus africanus. Proc Natl Acad Sci U S A (2009) 1.66
A comprehensive view of nuclear receptor cancer cistromes. Cancer Res (2011) 1.64
Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids (2004) 1.63
Self-directed self-assembly of nanoparticle/copolymer mixtures. Nature (2005) 1.62
Cyclooxygenase-2-derived prostaglandin E₂ promotes injury-induced vascular neointimal hyperplasia through the E-prostanoid 3 receptor. Circ Res (2013) 1.61
Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med (2008) 1.61
The role of histone acetylation in SMN gene expression. Hum Mol Genet (2005) 1.56
The genetics and neuropathology of Alzheimer's disease. Acta Neuropathol (2012) 1.56
The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. J Clin Invest (2002) 1.56
Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann Neurol (2005) 1.55
Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol (2011) 1.54
Systemic trafficking of plant virus nanoparticles in mice via the oral route. Virology (2005) 1.53
A novel Crumbs3 isoform regulates cell division and ciliogenesis via importin beta interactions. J Cell Biol (2007) 1.53
Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol (2013) 1.52
Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol (2008) 1.52
Hydrogen-rich saline reduces the oxidative stress and relieves the severity of trauma-induced acute pancreatitis in rats. J Trauma Acute Care Surg (2012) 1.50
Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis (2006) 1.49
The Fbw7/human CDC4 tumor suppressor targets proproliferative factor KLF5 for ubiquitination and degradation through multiple phosphodegron motifs. J Biol Chem (2010) 1.48
An experimental design to study adipocyte stem cells for reconstruction of calvarial defects. J Craniofac Surg (2009) 1.47
Genome-scale transcriptome analysis of the desert poplar, Populus euphratica. Tree Physiol (2011) 1.47
Prioritizing risk pathways: a novel association approach to searching for disease pathways fusing SNPs and pathways. Bioinformatics (2008) 1.46
A cone-beam computed tomography study of maxillary first permanent molar root and canal morphology in a Chinese population. J Endod (2010) 1.45
Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. J Clin Invest (2007) 1.45
Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J Neurochem (2002) 1.44
Surface modification of tobacco mosaic virus with "click" chemistry. Chembiochem (2008) 1.43
Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia (2005) 1.42
Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. Arch Neurol (2006) 1.42
Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol Res (2009) 1.42
Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest (2003) 1.42